The statistic shows the number of employees at pharmaceutical company Pfizer from 2006 to 2024. Pfizer Inc. is a multinational pharmaceutical corporation. The company is headquartered in Midtown Manhattan, New York City. In 2024, Pfizer employed approximately ****** persons around the world. The highest number of employees at Pfizer was reported in 2009, with almost *** thousand employed persons. Pfizer company factsPfizer is a pharmaceutical corporation with its headquarters in New York City, United States. It was founded in **** by Charles Pfizer and Charles Erhart in Brooklyn, New York. Their first product was an antiparasitic called santonin. Currently, Pfizer produces pharmaceutical products for a wide range of medical sectors such as immunology, cardiology, and neurology. Global revenue at Pfizer reached a record-high of over 100 billion U.S. dollars in 2022. Pfizer is active in many countries around the globe. Its research and development activities are focused on the discovery of small molecules as well as large-molecules (biologics), and the development of vaccines. The total number of employees working for Pfizer has decreased from ******* in 2009 to below ****** in 2021. After a merger with Wyeth in 2009, Pfizer cut over ****** employees. Pfizer has been named one of Canada’s top 100 employers by Maclean’s magazine in 2007, but has also been subject to controversy in employment in other countries, like in the United States.

In fiscal year 2024, the total number of employees at Pfizer was 81,000. The employee count decreasedby 7,000 from 88,000 (in 2023) to 81,000 (in 2024). It represents a -7.95% year-over-year decline in employee count.

Pfizer reported 81K in Employees for its fiscal year ending in December of 2024. Data for Pfizer | PFE - Employees Total Number including historical, tables and charts were last updated by Trading Economics this last August in 2025.

In 2022, the number of employees working in Pfizer SL Spain amounted to *** people, down from *** workers reported a year earlier. The Spanish subsidiary of the multinational pharmaceutical company Pfizer experienced a significant decrease in its number of employees between 2010 and 2017, reducing its headcount from around ***** to *** employees. Since then, the number of individuals working for Pfizer S.L. Spain has increased.

Revenues generated from outside the United States accounted for almost two thirds of Pfizer's total revenue in 2024. During that year, the company generated revenues of roughly ** billion U.S. dollars in countries outside the United States. China emerges as an important market Pfizer sells its pharmaceutical products in more than *** countries worldwide, with the United States, China, and Japan being among the major national markets. In 2024, the United States alone contributed a share of more than ** percent. In terms of geographic area, emerging markets – which include China – generated revenues of approximately *** billion U.S. dollars in 2024. Analyzing Pfizer’s global operations In 2024, Pfizer had approximately 81,000 employees worldwide. The American company had ** manufacturing sites in countries ranging from Belgium to Singapore, each producing products that serviced the company’s commercial division. Pfizer also had several facilities that focused on research and development projects, many of which were located in North America.

Pfizer's CEO salary and other executives compensation in 2024 was as follows: A. Bourla Chairman and Chief Executive Officer at Pfizer, received a total compensation of $24.65 M in 2024, M. Dolsten Chief Scientific Officer, President, Pfizer Research & Development at Pfizer, received a total compensation of $9.74 M in 2024, A. Malik Chief U.S. Commercial Officer, EVP at Pfizer, received a total compensation of $8.29 M in 2024, D. Denton Chief Financial Officer, EVP at Pfizer, received a total compensation of $8.12 M in 2024, C. Boshoff Chief Scientific Officer and President, Research & Development at Pfizer, received a total compensation of $7.85 M in 2024.

Pfizer is a global pharmaceutical company and among the top pharmaceutical companies in the world. Pfizer is headquartered in New York City. In 2024, the company's total revenue stood at **** billion U.S. dollars. Pfizer’s global positioning Pfizer’s products are available in many countries worldwide and as of 2024, the company had more than *** research and development projects in the pipeline. For several years, Pfizer was the top pharmaceutical company based on global prescription drug sales and is among the leading pharmaceutical companies based on research and development (R&D) spending. Pfizer’s largest segment is Innovative Health (IH). The Innovative Health business focuses on various rare diseases, vaccines, immunology and internal medicine to name a few. Pfizer’s top products In 2024, products from the Prevnar family were among Pfizer's top products based on revenue. However, Pfizer has several other drugs that are also well-known. For example, Lipitor (atorvastatin calcium) is used in the treatment of high cholesterol. Over the years, however, Lipitor revenues have been on the decline due to patent loss, yet it remains part of Pfizer’s top products. One of Pfizer’s most well-known products, Viagra (sildenafil citrate), used in the treatment of erectile disfunction, has also been on the decline with 2019 having the lowest revenues on record. The low revenues are mainly attributable to Viagra’s loss of patent exclusivity in the U.S. in December 2017.

Pfizer Des Employés Nombre total - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Aug 2025.Data for Pfizer | Des Employés | Nombre total including historical, tables and charts were last updated by Trading Economics this last August in 2025.

Number of AEs by participant gender and vaccine dose: Mean (S.D) number of AEs reported by male versus female HCWs for all three BNT162b2/Pfizer doses and the seasonal Influenza vaccine.

As of October 27, 2022, around 131.8 million coronavirus (COVID-19) vaccinations were recorded in South Korea. At the beginning of the vaccination campaign, the Korean government announced a COVID-19 vaccination plan for employees under the age of 65 in nursing hospitals or facilities, high-risk medical institutions, and the first responding group including emergency personnel or quarantine personnel, etc. The AstraZeneca vaccine was to be used for this priority group and the vaccination was scheduled to take place from February until May. Furthermore, vaccinations were planned for staff in hospitals treating COVID-19 patients, and the Pfizer vaccine was to be used for this group. South Korea's handling of the coronavirus (COVID-19) was initially widely praised, though the government's handling of vaccine distribution has been criticized.

For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

Pfizer Karyawan Jumlah Total - Nilai saat ini, data historis, perkiraan, statistik, grafik dan kalender ekonomi - Jul 2025.Data for Pfizer | Karyawan | Jumlah Total including historical, tables and charts were last updated by Trading Economics this last July in 2025.

The global market for small molecule sterile injectable drugs is experiencing robust growth, driven by several key factors. The increasing prevalence of chronic diseases requiring injectable therapies, such as cancer, autoimmune disorders, and infectious diseases, fuels demand. Furthermore, advancements in drug delivery technologies, such as liposomal formulations and targeted drug delivery systems, are improving efficacy and patient compliance, thereby expanding the market. Technological innovations also encompass the development of novel small molecule drugs with improved therapeutic profiles, further stimulating market expansion. The growing geriatric population, particularly susceptible to chronic illnesses, presents another significant driver. While regulatory hurdles and stringent quality control requirements represent potential restraints, the market's inherent growth trajectory is expected to outweigh these challenges. Competitive landscape analysis reveals a significant number of established pharmaceutical companies dominating the market, including Gilead Sciences, Pfizer, and AstraZeneca, alongside several smaller, specialized players. These companies are actively involved in research and development, pursuing novel drug candidates and improving existing delivery methods to maintain their market positions. Strategic partnerships, mergers, and acquisitions are frequently employed to accelerate innovation and consolidate market share. The projected Compound Annual Growth Rate (CAGR) suggests a substantial increase in market value over the forecast period (2025-2033). Assuming a conservative CAGR of 7% (a reasonable estimate given the pharmaceutical industry's typical growth trends), and a 2025 market size of $15 billion (a plausible estimate based on the presence of major players and the significance of the injectable drug market), the market is poised for significant expansion. Regional variations in market growth are expected, with North America and Europe likely maintaining dominant positions due to high healthcare expenditure and advanced healthcare infrastructure. However, emerging markets in Asia-Pacific and Latin America are demonstrating promising growth potential, driven by rising healthcare awareness and increased affordability of medications. The segmentation of the market, while not explicitly detailed, would likely involve drug classifications (e.g., antibiotics, anticancer agents, etc.), delivery methods, and therapeutic applications.

The global sterile dry powder active pharmaceutical ingredient (API) market is experiencing robust growth, driven by the increasing demand for injectable drugs and the advantages of powder formulations in terms of stability and ease of reconstitution. The market size in 2025 is estimated at $15 billion, reflecting a considerable expansion from previous years. A compound annual growth rate (CAGR) of 7% is projected from 2025 to 2033, indicating a significant market expansion over the forecast period. This growth is fueled by several key factors, including the rising prevalence of chronic diseases requiring injectable therapies, advancements in drug delivery technologies (e.g., lyophilization, spray drying), and a growing focus on personalized medicine, which often utilizes sterile injectable formulations. The increasing adoption of biosimilars and generics also contributes to market expansion as these often leverage sterile dry powder API technologies to reduce costs and improve efficacy. However, stringent regulatory requirements, particularly regarding sterility and quality control, pose a challenge to market growth. Furthermore, the high cost of manufacturing and the specialized expertise required for handling sterile APIs create barriers to entry, limiting the number of active players. The market is segmented by API type (e.g., antibiotics, anticancer drugs, vaccines), delivery method (e.g., lyophilized, spray-dried), and therapeutic area (e.g., oncology, infectious diseases). Key players like Dr. Reddy's Laboratories, Lonza Group, and Pfizer are investing heavily in research and development and expanding their manufacturing capabilities to meet growing demand. The geographical distribution shows significant market presence in North America and Europe, driven by strong regulatory frameworks and higher healthcare spending. However, emerging markets in Asia-Pacific are expected to witness substantial growth in the coming years, fueled by rising disposable incomes and increasing healthcare infrastructure development. Strategic partnerships, mergers and acquisitions, and continuous innovation in formulation technologies are key strategies employed by companies to maintain a competitive edge and capture market share in this dynamic sector.

The global Droperidol Injection market is experiencing robust growth, projected to reach a market size of $500 million by 2025, with a Compound Annual Growth Rate (CAGR) of 7% from 2025 to 2033. This expansion is driven by several key factors. The increasing prevalence of conditions requiring antiemetic and antipsychotic medication, such as postoperative nausea and vomiting (PONV), delirium tremens, and schizophrenia, fuels demand. Furthermore, the growing number of surgical procedures worldwide contributes significantly to market growth. The preference for injectable formulations due to their rapid onset of action and ease of administration in hospital settings also boosts market adoption. While potential regulatory hurdles and the availability of alternative therapies represent constraints, the overall market outlook remains positive, particularly in developed nations with advanced healthcare infrastructure. Segment-wise, the 2.5mg/ml dosage form likely holds the largest market share due to its widespread use and cost-effectiveness, while the hospital application segment dominates due to higher procedural volumes and the need for immediate intervention. Growth is anticipated across all regions, with North America and Europe currently leading the market due to higher healthcare expenditure and established healthcare systems. However, emerging economies in Asia-Pacific and the Middle East & Africa are expected to show significant growth potential driven by increasing healthcare investments and rising awareness of the benefits of droperidol injections. Competition in the market is intense, with established pharmaceutical companies like Pfizer and American Regent alongside other regional players vying for market share through product differentiation and strategic partnerships. The market's expansion is expected to be fueled by continuous technological advancements, leading to improved formulations with better efficacy and fewer side effects. Moreover, ongoing research into the therapeutic applications of droperidol will likely open new avenues for growth. The introduction of innovative delivery systems and formulations could also contribute to market expansion. However, pricing pressures and the need to comply with stringent regulatory approvals pose challenges. Companies are focusing on building stronger distribution networks and strategic partnerships to effectively penetrate target markets, particularly in emerging economies. The market's future trajectory will depend significantly on ongoing clinical trials, regulatory approvals for new indications, and the success of marketing strategies employed by key players. Overall, the market for Droperidol Injection offers substantial opportunities for growth and investment in the foreseeable future.

The Neurological Disorder Drugs Market, valued at approximately $XX million in 2025, is projected to experience robust growth, exhibiting a Compound Annual Growth Rate (CAGR) of 5.60% from 2025 to 2033. This expansion is fueled by several key drivers. The rising prevalence of neurological disorders like Alzheimer's disease, Parkinson's disease, epilepsy, and multiple sclerosis across the globe is a significant contributor. An aging global population, coupled with increased awareness and improved diagnostic capabilities, is leading to a higher number of diagnosed cases, thus boosting demand for effective treatments. Furthermore, continuous advancements in drug development and research are resulting in the introduction of novel therapies with enhanced efficacy and reduced side effects, further stimulating market growth. The market is segmented by disorder type (Epilepsy, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Disorders), drug type (Cholinesterase Inhibitors, NMDA Receptor Antagonists, Antiepileptic, Antipsychotic and Antidepressant, Other Drugs), and distribution channels (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies). North America currently holds a substantial market share, driven by high healthcare expenditure and advanced medical infrastructure. However, emerging economies in Asia-Pacific and other regions are expected to witness significant growth in the coming years, fueled by increasing healthcare investments and rising disposable incomes. Despite the positive outlook, market growth may be somewhat constrained by high drug prices, stringent regulatory approvals, and the complexities associated with treating neurological disorders. The competitive landscape is dominated by major pharmaceutical companies including Merck & Co Inc, AstraZeneca, Abbott, F Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc, Sanofi, Bayer AG, Johnson & Johnson, and Teva Pharmaceutical Industries Ltd. These companies are engaged in intense research and development activities to develop innovative therapies and expand their market presence. Strategic collaborations, mergers, acquisitions, and licensing agreements are common strategies employed by these players to strengthen their product portfolios and gain a competitive edge. The future of the Neurological Disorder Drugs Market is promising, with continuous innovation and expansion into new therapeutic areas expected to drive further growth in the forecast period. However, addressing challenges related to affordability and access to these life-changing medications remains crucial for maximizing the market's potential and ensuring that patients benefit from these advancements. Recent developments include: In March 2023, the development of an oral, brain-penetrant, dual inhibitor of TYK2 and JAK1 for treating neurological illnesses was announced by Biohaven Ltd., except for the China region., In March 2023, Acadia Pharmaceuticals Inc. announced that the United States FDA had approved DAYBUE (trofinetide) for treating Rett syndrome in adult and pediatric patients two years of age and older.. Key drivers for this market are: High Prevalence of Neurological Diseases, Rising Awareness for Early Disease Diagnosis; Increasing Number of Research and Development for Neurological Diseases. Potential restraints include: High Prevalence of Neurological Diseases, Rising Awareness for Early Disease Diagnosis; Increasing Number of Research and Development for Neurological Diseases. Notable trends are: The Alzheimer's Disease Segment is Expected to Hold a Significant Share in the Neurological Disorders Drugs Market Over the Forecast Period.

Brand name pharmaceutical manufacturers in the US are some of the most lucrative in the world. Consumers in the US use and spend more on prescription drugs than any other country, making manufacturers central to meeting this demand and supporting public health. This role was evident during the COVID-19 pandemic, as brand name pharma producers researched, produced and distributed vital vaccines in record time. Aside from vaccine development, domestic manufacturers can attribute rising spending on brand name drugs to several factors, including an aging population, expanding health coverage, new drug approvals and medical advances in expensive specialty areas like rare diseases and oncology. Still, mounting scrutiny facing brand name pharma makers focuses on pricing policies and patent protections, suggesting that the industry’s strong performance indicates monopolistic practices and price hikes rather than rising prescription drug use. In all, revenue has been growing at a CAGR of 5.8% over the past five years to an estimated $302.9 billion, including expected growth of 3.7% in 2025. One of the most notable pieces of regulation to date impacting brand name pharma producers is the Inflation Reduction Act (IRA). Passed in 2022, the IRA introduces multiple provisions impacting the industry, permanently reshaping how pharmaceutical manufacturers will operate. Key provisions of the IRA include Medicare’s ability to negotiate drug prices, rebates for excessive price increases and an out-of-pocket spending cap. While a substantial body of criticism and legal challenges surrounding the IRA exist, it marks the movement to lower drug spending for patients and the federal government. While brand name pharma manufacturers will navigate an evolving environment, the industry’s performance will remain robust. Ongoing R&D investments will yield new, innovative therapies to address unmet needs, bolstering product pipelines. At the same time, an increasing prevalence of chronic illness and a growing number of over 65 adults will support a steep demand for prescription drugs. Merger and acquisition activity seen in recent years won’t slow as incumbents look for ways to diversify pipelines, access new technologies or reach new markets as pressures from patent cliffs and the regulatory landscape mount. Still, revenue growth will be strong, increasing at a CAGR of 3.4% to an estimated $358.1 billion over the next five years

Health care workers perception of COVID-19 infection and vaccination.

Advertising costs of Pfizer totaled approximately *** billion U.S. dollars in 2024, a decrease of *** million U.S. dollars compared to the previous year, but still one of the higher amounts in the provided period. What are Pfizer’s biggest expenses? Pfizer spent around **** billion U.S. dollars on selling, informational, and administrative expenses in 2024 – this segment, which includes advertising costs, accounted for the company’s second-biggest expense during the year. Spending on research and development is another of Pfizer’s highest costs, but discovering new drugs and adding value to existing products is vital to the success of the company. Pfizer’s home in the city that doesn’t sleep As of 2024, Pfizer had ** plants around the world and a global workforce of approximately ****** employees. The company’s global headquarters is on **** Street in Midtown Manhattan, New York City. Pfizer’s roots in the city can be traced back to **** when cousins Charles Pfizer and Charles Erhart founded the company in Brooklyn.

The global travelers' vaccination market, valued at $5.552 billion in 2025, is poised for significant growth driven by increasing international travel, rising awareness of vaccine-preventable diseases, and expanding government initiatives promoting vaccination. The market's Compound Annual Growth Rate (CAGR) is projected to be in the range of 7-9% over the forecast period (2025-2033), fueled by a surge in medical tourism and the growing prevalence of infectious diseases in various regions. Key segments driving growth include vaccines against Meningococcal, Japanese Encephalitis, Yellow Fever, Hepatitis, and Cholera, with demand particularly strong among tourists, students, and workers undertaking international assignments. The market is highly competitive, with major players such as GSK, Sanofi Pasteur, Merck, Pfizer, and several prominent Asian manufacturers actively engaged in research and development, leading to innovations in vaccine technology and delivery systems. Geographic expansion into emerging markets with rising disposable incomes and increased outbound travel is another key growth factor. However, challenges include vaccine hesitancy, inconsistent vaccine accessibility across regions, and the emergence of vaccine-resistant strains of diseases. Continued growth in the travelers' vaccination market is anticipated due to several factors. The increasing affordability of international travel, coupled with a rise in the number of medical tourism activities, is expected to fuel demand. The market will benefit from ongoing efforts by public health organizations to raise awareness of the importance of vaccination for travelers and to streamline vaccination processes. The development of newer, more effective, and convenient vaccines, such as combination vaccines or vaccines with extended shelf lives, will positively influence market expansion. Regional disparities in vaccine access remain a challenge, but ongoing efforts by international organizations and governmental bodies aim to address these gaps. The market's competitive landscape is expected to intensify with continued product innovation and strategic partnerships among manufacturers to ensure wide availability of safe and effective vaccines.

The Doxorubicin market, valued at approximately $XX million in 2025 (assuming a logical estimation based on the provided CAGR of 6.50% and market size “XX”), is projected to experience robust growth throughout the forecast period (2025-2033). This expansion is primarily driven by the increasing prevalence of cancers treatable with Doxorubicin, including leukemia, lymphoma, and breast cancer. Further fueling market growth is the ongoing research and development into novel Doxorubicin formulations and delivery methods aimed at improving efficacy and minimizing adverse effects. The market is segmented by various factors, including route of administration (intravenous, intramuscular), dosage form (injections, liposomal), and application area (oncology). Competitive dynamics are shaped by the presence of both large multinational pharmaceutical companies like Baxter International Inc., Johnson & Johnson (Janssen Pharmaceutical), and Pfizer Inc., and smaller, specialized players like SRS Pharmaceuticals Pvt Ltd and Cadila Pharmaceuticals, each vying for market share through product innovation and strategic partnerships. Geographic variations in healthcare infrastructure and regulatory frameworks influence regional market penetration, with North America and Europe anticipated to retain significant market share due to established healthcare systems and high cancer incidence rates. However, emerging markets in Asia-Pacific and Latin America are expected to exhibit faster growth rates due to increasing healthcare spending and rising cancer prevalence. Despite the overall positive growth outlook, the Doxorubicin market faces certain challenges. These include the inherent toxicity associated with Doxorubicin, necessitating careful monitoring and management of side effects. Furthermore, the emergence of drug resistance and the development of alternative cancer therapies present potential restraints to market growth. However, ongoing research efforts focused on overcoming these limitations and developing targeted drug delivery systems are expected to mitigate these challenges to some extent. The market's future trajectory hinges on successful clinical trials for novel Doxorubicin formulations, regulatory approvals, and effective market access strategies employed by key players. The continued focus on improving patient outcomes and reducing treatment-related side effects will remain a central theme in shaping this market's future. Recent developments include: In October 2021, Padagis, in partnership with Ayana Pharma Ltd, received approval from the US FDA to launch its AB-rated generic version of Doxil (Doxorubicin Liposome Injection)., In August 2021, Genentech announced positive results from the pivotal Phase III POLARIX trial investigating Polivy (polatuzumab vedotin) in combination with Rituxan (rituximab) plus cyclophosphamide, doxorubicin, and prednisone (R-CHP) versus Rituxan plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). The company stated that it met the primary endpoint by demonstrating significantly improved and clinically meaningful progression-free survival in people with previously untreated diffuse large B-cell lymphoma (DLBCL).. Key drivers for this market are: Increasing Number of Companies Manufacturing Doxorubicin, Rising Application of Doxorubicin in Cancer Treatment; Increasing Prevalence of Cancer Worldwide. Potential restraints include: Increasing Number of Companies Manufacturing Doxorubicin, Rising Application of Doxorubicin in Cancer Treatment; Increasing Prevalence of Cancer Worldwide. Notable trends are: Doxorubicin Market in Breast Cancer Segment is Expected to Witness Better CAGR Over the Forecast Period.